Renal Cell Carcinoma: New Developments

Future developments in renal cell carcinoma.

BACKGROUND The development of targeted agents has substantially improved prognoses for patients with metastatic renal cell carcinoma (mRCC). Four targeted agents are approved for the treatment of mRCC in Europe (bevacizumab given in combination with interferon-alfa, sorafenib, sunitinib and temsirolimus) and a number of investigational agents have shown potential in this setting. DESIGN This ...

Sarcomatoid Transrormation of Chromophobe Renal Cell Carcinoma

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib

With the recent approval of pazopanib, an oral multitargeted tyrosine kinase inhibitor which potently targets vascular endothelial growth factor receptors 1-3, platelet-derived growth factor, and c-kit, six agents are now available for use in the management of metastatic renal cell carcinoma (RCC). Pazopanib has shown improved progression-free survival compared with placebo in treatment-naïve o...

Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.

Renal cell carcinoma (RCC) affects 38,000 individuals in the U.S. yearly. Seventy-five percent of cases are clear-cell carcinomas, and a majority is driven by dysfunction of the von Hippel-Lindau (VHL) gene. VHL loss of function and other non-VHL pathways leading to RCC share aberrant activation of the hypoxic response, such as upregulation of vascular endothelial growth factor (VEGF) and conse...

Dyspnea as the First Manifestation of Silent Renal Cell Carcinoma

Renal cell carcinoma (RCC) accounts for only 3% of adult malignancies, and the lung is the most common site of metastasis of this tumor, which may be accompanied by pleural metastasis. However, solitary pleural involvement is very rare and its presentation with dyspnea as the first manifestation of RCC is extremely rare.We describe a 39-year-old male with episodes of dyspnea dating back 6...